Enfortumab Vedotin Combo Shows Activity in Metastatic Urothelial Carcinoma
Pembrolizumab in combination with enfortumab vedotin-ejfv demonstrates a manageable safety profile in the treatment of metastatic urothelial carcinoma in the EV-103 trial.
Darolutamide Prolongs Time to Treatment Discontinuation In Prostate Cancer
The treatment discontinuation rate was 30.4% for darolutamide, 40.8% for enzalutamide, and 46.0% for apalutamide among patients with nonmetastatic prostate cancer, according to a recent analysis.
Pembrolizumab Yields Clinical Activity in Bladder Cancer Subtype
Pembrolizumab appears to achieve antitumor activity in terms of disease-free survival in patients with Bacillus calmette-guerin–unresponsive, papillary high–risk, non-muscle invasive bladder cancer.
Darolutamide Demonstrates Long-Term Safety in Nonmetastatic CRPC
Long-term safety data from the phase 3 ARAMIS rollover trial support the use of darolutamide in patients with nonmetastatic castration-resistant prostate cancer, according to an expert from the Carolina Urologic Research Center.
Novel PSMA-TRT-based Triplet Regimen Appears Effective in Prostate Cancer
All patients with chemo-naïve metastatic castration-resistant prostate cancer experienced PSA decline, and half the cohort experienced a PSA decline greater than 50% after treatment with a novel PSMA-targeted radionuclide therapy.
High ORR Associated With Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Cancer
Findings from Cohort K of the EV-103 trial demonstrated a 64.5% overall response rate with enfortumab vedotin plus pembrolizumab in metastatic urothelial cancer.
Perioperative Use of Nivolumab Yields No RFS Boost in RCC
Phase 3 data regarding perioperative nivolumab did not show recurrence-free survival benefit, but data from the study may help inform future research.
Darolutamide Does Not Alter Metastatic Progression Pattern in nmCRPC in ARAMIS
Metastatic progression pattern with darolutamide appears to be unaltered in nonmetastatic castration-resistant prostate cancer, despite the agent resulting in better survival outcomes.
Data Support Safe Interaction of Darolutamide and Cabazitaxel in mCRPC
Unlike with enzalutamide, it appears darolutamide does not affect systemic exposure of cabazitaxel in patients with metastatic castration-resistant prostate cancer.
177Lu-PSMA-617 Has Similar Survival, But Increased PROs Vs Cabazitaxel in mCRPC
Similar overall survival, better patient-reported outcomes, and fewer adverse effects were observed when patients were treated with 177Lu-PSMA-617 vs cabazitaxel in metastatic castration-resistant prostate cancer.
Avelumab Maintenance Yields Survival Benefit in First-Line Advanced Urothelial Carcinoma, Regardless of Second-Line Therapy
An exploratory analysis of the JAVELIN Bladder 100 study indicated long-term overall survival benefit for patients with advanced urothelial carcinoma who received avelumab maintenace, without regard for treatment given in the second-line setting.
Cabozantinib After Chemotherapy Yields Similar Efficacy Vs Placebo in Advanced Urothelial Carcinoma
Results from the phase 2 ATLANTIS trial did not show a benefit of cabozantinib in patients with advanced urothelial carcinoma compared with the placebo, but the treatment appeared to be tolerable.
Disease-Free Survival Benefits Persist With Adjuvant Pembrolizumab in RCC
Updated data from the KEYNOTE-564 trial that were reported at 2022 ASCO GU show continuous disease-free survival advantage with pembrolizumab vs placebo as adjuvant therapy for renal cell carcinoma.
Patients With nmCRPC Continue to See Benefit With Darolutamide Despite Comorbidities, Concomitant Medications
Data from the ARAMIS trial that were presented at 2022 ASCO GU showed that darolutamide benefit for patients with nonmetastatic castration-resistant prostate cancer was consistent regardless of the number of comorbidities or concomitant medications.
Pembrolizumab/Olaparib Combo May Yield Better Responses in mCRPC Regardless of HRR Status
Patients with metastatic castration-resistant prostate cancer experienced an improvement in prostate-specific antigen following treatment with pembrolizumab and olaparib.
Abiraterone Plus ADT and Docetaxel to Treat de novo mCSPC Improved rPFS
Adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved radiographic progression-free survival for men with de novo metastatic castration-sensitive prostate cancer.
Lower Likelihood of Genomic Profiling Observed for Men With African Ancestry
Disparities regarding comprehensive genomic profiling came to light during a presentation at the 2021 ASCO Annual Meeting.
Trimodal Pembrolizumab-Based Combo Shows Safety and Efficacy Treating MIBC
Pembrolizumab plus gemcitabine and concurrent hypofractionated radiotherapy to treat patients with MIBC demonstrated safety and efficacy.
HPN424 Shows Promise in mCRPC Pretreated With Systemic Therapy
Phase 1/2 data presented at the 2021 ASCO Annual Meeting for the novel PSMA-targeting agent HPN424 show tumor responses in patients with pretreated metastatic castration-resistant prostate cancer.
Safety and Efficacy of Investigational Agents Under Evaluation in Umbrella Study for Advanced RCC
The safety and efficacy of experimental combinations of investigational agents are being analyzed as treatment for advanced clear cell renal cell carcinoma as part of a phase 1b/2 umbrella platform study.
Survival Advantage Is Experienced by Patients Receiving Apalutamide Added to ADT for mCSPC
Compared with androgen-deprivation therapy alone, patients with metastatic castration-sensitive prostate cancer had better outcomes when apalutamide was added to systemic therapy.
Pouch Diversion May Lead to Decision Regret in Patients Undergoing Cystectomy
Patients who underwent pouch diversion reported significantly more regret than patients undergoing neobladder or ileal conduit.
Radiation Therapy May Provide Some Benefit to Patients with High-Risk NMIBC
This study found that radiation therapy may provide some benefit for patients with high-risk non–muscle invasive bladder cancer, though the quality of evidence in this current setting is low.
Durvalumab Monotherapy, Combination Fail to Improved OS in Metastatic Urothelial Carcinoma
Durvalumab, with or without tremelimumab, failed to meet its primary end point of overall survival in patients with metastatic urothelial cancer.
Ipi-Nivo Combination Yields Improved Responses After 4-Year Follow-Up in Advanced RCC
The combination use of nivolumab plus ipilimumab, compared with sunitinib, continued to show benefit during a 4-year follow-up in patients with advanced renal cell carcinoma.
2 Clarke Drive Cranbury, NJ 08512